ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
August 06, 2021Aprea Therapeutics, Inc. today announced that the FDA has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. -
Aprea Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246
August 03, 2017Aprea Therapeutics announced the first patient was enrolled in a Phase Ib/II clinical study of APR-246 in platinum-resistant high-grade serous ovarian cancer (HGSOC).
Pharma Sources Insight January 2025
